Link came from Prescient's website! There is the link between PTX 100 and myeloma.
Prescient’s Phase 1b trial is a PK/PD “BASKET” study which is currently underway in Australia with an aim to determine the optimal dose and treatment schedule of PTX-100 in a hematological and solid malignancies such as myeloma, T-cell lymphomas, gastric and pancreatic cancers. This study is being conducted under the guidance of Professor H. Miles Prince, AM, a globally renowned oncologist. The readouts are expected in 2H 2020. The Phase 1 trial of PTX-100 has been previously completed and it was found to be well-tolerated and achieved stable disease.
PTX Price at posting:
8.2¢ Sentiment: Buy Disclosure: Held
